Strain Name:

129S-Trp53tm2Tyj/J

Stock Number:

008652

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use
Common Names: p53LSL.R172H 129svj;    
These mice carry a conditional point-mutant allele of the transformation related protein 53 gene (p53R172H; structural mutant homologous to human p53 codon 175). The conditional allele is functionally equivalent to a null mutation. Mice have all the phenotypic issues of p53 knockout mice and therefore have some decreased viability of homozygotes. Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Coisogenic; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
 
Donating InvestigatorDr. Tyler Jacks,   Massachusetts Institute of Technology

Description
These mice carry a conditional point-mutant allele of the transformation related protein 53 gene (p53R172H; structural mutant homologous to human p53 codon 175). The conditional allele is functionally equivalent to a null mutation. Mice have all the phenotypic issues of p53 knockout mice and therefore have some decreased viability of homozygotes. Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein.

Development
A targeting vector was designed to place a loxP-flanked stop cassette in intron 1 and an R172H missense mutation into exon 5. The construct was electroporated into 129S4/SvJae-derived J1 embryonic stem (ES) cells. The strain was maintained on a 129S4/SvJae background by the donating laboratory.

Related Strains

View Strains carrying other alleles of Trp53     (27 strains)

Additional Web Information

Introduction to Cre-lox technology

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Adrenocortical Carcinoma, Hereditary; ADCC   (TP53)
Basal Cell Carcinoma, Susceptibility to, 7; BCC7   (TP53)
Breast Cancer   (TP53)
Colorectal Cancer; CRC   (TP53)
Glioma Susceptibility 1; GLM1   (TP53)
Hepatocellular Carcinoma   (TP53)
Li-Fraumeni Syndrome 1; LFS1   (TP53)
Nasopharyngeal Carcinoma   (TP53)
Osteogenic Sarcoma   (TP53)
Pancreatic Cancer   (TP53)
Papilloma of Choroid Plexus; CPP   (TP53)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Trp53tm2Tyj/Trp53tm2Tyj

        involves: 129S4/SvJae   (conditional)
  • cellular phenotype
  • early cellular replicative senescence
    • ovarian surface epithelium cells transfected with a cre-expressing adenovirus exhibit very limited proliferation potential and undergo senescence sooner than control cells that become immortalized   (MGI Ref ID J:175978)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Apoptosis Research
Endogenous Regulators

Cancer Research
Increased Tumor Incidence
      Lymphomas
      Other Tissues/Organs
      Other Tissues/Organs: osteosarcoma
Toxicology
Tumor Suppressor Genes

Immunology, Inflammation and Autoimmunity Research
Intracellular Signaling Molecules

Research Tools
Cre-lox System
      loxP-flanked Sequences
Toxicology Research
      drug/compound testing

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Trp53tm2Tyj
Allele Name targeted mutation 2, Tyler Jacks
Allele Type Targeted (Floxed/Frt)
Common Name(s) LSL-Trp53R172H; p53 LSL-R172H; p53LSL(dot)R172H; p53LSL-R172H;
Mutation Made ByDr. Tyler Jacks,   Massachusetts Institute of Technology
Strain of Origin129S4/SvJae
ES Cell Line NameJ1
ES Cell Line Strain129S4/SvJae
Gene Symbol and Name Trp53, transformation related protein 53
Chromosome 11
Gene Common Name(s) BCC7; LFS1; P53; p44;
Molecular Note A targeting construct was designed to insert a loxP flanked stop cassette into intron 1 and an R172H missense mutation into exon 5. [MGI Ref ID J:95316]

Genotyping

Genotyping Information

Genotyping Protocols

Trp53tm2Tyj, Separated PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119(6):847-60. [PubMed: 15607980]  [MGI Ref ID J:95316]

Additional References

Trp53tm2Tyj related

Bayne LJ; Beatty GL; Jhala N; Clark CE; Rhim AD; Stanger BZ; Vonderheide RH. 2012. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6):822-35. [PubMed: 22698406]  [MGI Ref ID J:189283]

Chugh R; Sangwan V; Patil SP; Dudeja V; Dawra RK; Banerjee S; Schumacher RJ; Blazar BR; Georg GI; Vickers SM; Saluja AK. 2012. A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med 4(156):156ra139. [PubMed: 23076356]  [MGI Ref ID J:189216]

Collins MA; Brisset JC; Zhang Y; Bednar F; Pierre J; Heist KA; Galban CJ; Galban S; di Magliano MP. 2012. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One 7(12):e49707. [PubMed: 23226501]  [MGI Ref ID J:195686]

Colvin EK; Susanto JM; Kench JG; Ong VN; Mawson A; Pinese M; Chang DK; Rooman I; O'Toole SA; Segara D; Musgrove EA; Sutherland RL; Apte MV; Scarlett CJ; Biankin AV. 2011. Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS One 6(12):e29075. [PubMed: 22220202]  [MGI Ref ID J:182325]

Cook N; Frese KK; Bapiro TE; Jacobetz MA; Gopinathan A; Miller JL; Rao SS; Demuth T; Howat WJ; Jodrell DI; Tuveson DA. 2012. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med 209(3):437-44. [PubMed: 22351932]  [MGI Ref ID J:182504]

Court H; Amoyel M; Hackman M; Lee KE; Xu R; Miller G; Bar-Sagi D; Bach EA; Bergo MO; Philips MR. 2013. Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J Clin Invest :. [PubMed: 24216479]  [MGI Ref ID J:204180]

Courtin A; Richards FM; Bapiro TE; Bramhall JL; Neesse A; Cook N; Krippendorff BF; Tuveson DA; Jodrell DI. 2013. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PLoS One 8(6):e67330. [PubMed: 23840665]  [MGI Ref ID J:203716]

DuPage M; Dooley AL; Jacks T. 2009. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4(7):1064-72. [PubMed: 19561589]  [MGI Ref ID J:201034]

Eser S; Reiff N; Messer M; Seidler B; Gottschalk K; Dobler M; Hieber M; Arbeiter A; Klein S; Kong B; Michalski CW; Schlitter AM; Esposito I; Kind AJ; Rad L; Schnieke AE; Baccarini M; Alessi DR; Rad R; Schmid RM; Schneider G; Saur D. 2013. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23(3):406-20. [PubMed: 23453624]  [MGI Ref ID J:197054]

Feig C; Jones JO; Kraman M; Wells RJ; Deonarine A; Chan DS; Connell CM; Roberts EW; Zhao Q; Caballero OL; Teichmann SA; Janowitz T; Jodrell DI; Tuveson DA; Fearon DT. 2013. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 110(50):20212-7. [PubMed: 24277834]  [MGI Ref ID J:205406]

Fendrich V; Schneider R; Maitra A; Jacobsen ID; Opfermann T; Bartsch DK. 2011. Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer. Neoplasia 13(2):180-6. [PubMed: 21403843]  [MGI Ref ID J:171634]

Frese KK; Neesse A; Cook N; Bapiro TE; Lolkema MP; Jodrell DI; Tuveson DA. 2012. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2(3):260-9. [PubMed: 22585996]  [MGI Ref ID J:193075]

Gruner BM; Hahne H; Mazur PK; Trajkovic-Arsic M; Maier S; Esposito I; Kalideris E; Michalski CW; Kleeff J; Rauser S; Schmid RM; Kuster B; Walch A; Siveke JT. 2012. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer. PLoS One 7(6):e39424. [PubMed: 22761793]  [MGI Ref ID J:187923]

Hingorani SR; Wang L; Multani AS; Combs C; Deramaudt TB; Hruban RH; Rustgi AK; Chang S; Tuveson DA. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7(5):469-83. [PubMed: 15894267]  [MGI Ref ID J:98936]

Hwang CI; Matoso A; Corney DC; Flesken-Nikitin A; Korner S; Wang W; Boccaccio C; Thorgeirsson SS; Comoglio PM; Hermeking H; Nikitin AY. 2011. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A 108(34):14240-5. [PubMed: 21831840]  [MGI Ref ID J:175978]

Ischenko I; Zhi J; Moll UM; Nemajerova A; Petrenko O. 2013. Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci U S A 110(10):3937-42. [PubMed: 23431158]  [MGI Ref ID J:196077]

Jackson EL; Olive KP; Tuveson DA; Bronson R; Crowley D; Brown M; Jacks T. 2005. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65(22):10280-8. [PubMed: 16288016]  [MGI Ref ID J:103407]

Kasinski AL; Slack FJ. 2012. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 72(21):5576-87. [PubMed: 22964582]  [MGI Ref ID J:191425]

Koso H; Takeda H; Yew CC; Ward JM; Nariai N; Ueno K; Nagasaki M; Watanabe S; Rust AG; Adams DJ; Copeland NG; Jenkins NA. 2012. Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. Proc Natl Acad Sci U S A 109(44):E2998-3007. [PubMed: 23045694]  [MGI Ref ID J:190371]

Lampson BL; Kendall SD; Ancrile BB; Morrison MM; Shealy MJ; Barrientos KS; Crowe MS; Kashatus DF; White RR; Gurley SB; Cardona DM; Counter CM. 2012. Targeting eNOS in pancreatic cancer. Cancer Res 72(17):4472-82. [PubMed: 22738914]  [MGI Ref ID J:191028]

Lehtonen S; Tienari J; Londesborough A; Pirvola U; Ora A; Reima I; Lehtonen E. 2008. CD2-associated protein is widely expressed and differentially regulated during embryonic development. Differentiation 76(5):506-17. [PubMed: 18177421]  [MGI Ref ID J:135527]

Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY. 2013. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10). Carcinogenesis 34(9):2090-8. [PubMed: 23689354]  [MGI Ref ID J:200524]

Li L; Hanahan D. 2013. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell 153(1):86-100. [PubMed: 23540692]  [MGI Ref ID J:197249]

Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ. 2010. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 107(1):246-51. [PubMed: 20018721]  [MGI Ref ID J:156461]

Neesse A; Frese KK; Bapiro TE; Nakagawa T; Sternlicht MD; Seeley TW; Pilarsky C; Jodrell DI; Spong SM; Tuveson DA. 2013. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A 110(30):12325-30. [PubMed: 23836645]  [MGI Ref ID J:198792]

Nobis M; McGhee EJ; Morton JP; Schwarz JP; Karim SA; Quinn J; Edward M; Campbell AD; McGarry LC; Evans TR; Brunton VG; Frame MC; Carragher NO; Wang Y; Sansom OJ; Timpson P; Anderson KI. 2013. Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer. Cancer Res 73(15):4674-4686. [PubMed: 23749641]  [MGI Ref ID J:199648]

Olive KP; Jacobetz MA; Davidson CJ; Gopinathan A; McIntyre D; Honess D; Madhu B; Goldgraben MA; Caldwell ME; Allard D; Frese KK; Denicola G; Feig C; Combs C; Winter SP; Ireland-Zecchini H; Reichelt S; Howat WJ; Chang A; Dhara M; Wang L; Ruckert F; Grutzmann R; Pilarsky C; Izeradjene K; Hingorani SR; Huang P; Davies SE; Plunkett W; Egorin M; Hruban RH; Whitebread N; McGovern K; Adams J; Iacobuzio-Donahue C; Griffiths J; Tuveson DA. 2009. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457-61. [PubMed: 19460966]  [MGI Ref ID J:149213]

Olson P; Chu GC; Perry SR; Nolan-Stevaux O; Hanahan D. 2011. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A 108(49):E1275-84. [PubMed: 22084065]  [MGI Ref ID J:180399]

Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR. 2012. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3):418-29. [PubMed: 22439937]  [MGI Ref ID J:189345]

Rad R; Cadinanos J; Rad L; Varela I; Strong A; Kriegl L; Constantino-Casas F; Eser S; Hieber M; Seidler B; Price S; Fraga MF; Calvanese V; Hoffman G; Ponstingl H; Schneider G; Yusa K; Grove C; Schmid RM; Wang W; Vassiliou G; Kirchner T; McDermott U; Liu P; Saur D; Bradley A. 2013. A Genetic Progression Model of Braf(V600E)-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention. Cancer Cell 24(1):15-29. [PubMed: 23845441]  [MGI Ref ID J:199307]

Reichert M; Takano S; von Burstin J; Kim SB; Lee JS; Ihida-Stansbury K; Hahn C; Heeg S; Schneider G; Rhim AD; Stanger BZ; Rustgi AK. 2013. The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. Genes Dev 27(3):288-300. [PubMed: 23355395]  [MGI Ref ID J:193476]

Seidler B; Schmidt A; Mayr U; Nakhai H; Schmid RM; Schneider G; Saur D. 2008. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc Natl Acad Sci U S A 105(29):10137-42. [PubMed: 18621715]  [MGI Ref ID J:140423]

Shen R; Wang Q; Cheng S; Liu T; Jiang H; Zhu J; Wu Y; Wang L. 2013. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models. Cancer Lett 339(1):135-43. [PubMed: 23887057]  [MGI Ref ID J:202529]

Szabova L; Yin C; Bupp S; Guerin TM; Schlomer JJ; Householder DB; Baran ML; Yi M; Song Y; Sun W; McDunn JE; Martin PL; Van Dyke T; Difilippantonio S. 2012. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 72(16):4141-53. [PubMed: 22617326]  [MGI Ref ID J:189304]

Tran K; Risingsong R; Royce DB; Williams CR; Sporn MB; Pioli PA; Gediya LK; Njar VC; Liby KT. 2013. The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis 34(1):199-210. [PubMed: 23042302]  [MGI Ref ID J:193646]

Tuveson DA; Hingorani SR. 2005. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 70:65-72. [PubMed: 16869739]  [MGI Ref ID J:116752]

Vermeulen L; Morrissey E; van der Heijden M; Nicholson AM; Sottoriva A; Buczacki S; Kemp R; Tavare S; Winton DJ. 2013. Defining stem cell dynamics in models of intestinal tumor initiation. Science 342(6161):995-8. [PubMed: 24264992]  [MGI Ref ID J:205193]

Winslow MM; Dayton TL; Verhaak RG; Kim-Kiselak C; Snyder EL; Feldser DM; Hubbard DD; DuPage MJ; Whittaker CA; Hoersch S; Yoon S; Crowley D; Bronson RT; Chiang DY; Meyerson M; Jacks T. 2011. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473(7345):101-4. [PubMed: 21471965]  [MGI Ref ID J:171810]

Wu R; Baker SJ; Hu TC; Norman KM; Fearon ER; Cho KR. 2013. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol 182(4):1391-9. [PubMed: 23499052]  [MGI Ref ID J:195346]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryWhen maintained as a live colony, heterozygotes may be bred. Homozygous mice develop tumors.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2450.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.
    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3185.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.
    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.5)